People diagnosed with lung cancer are usually in a terrible state of mind. Some even cannot decide which treatment they should go with. There are many options for non-small cell lung cancer treatment like radiation, chemotherapy, surgery and targeted treatments. These treatment options can be used alone or in combination, which depends upon the patient’s condition. A newer way to treat cancer is the use of vaccines that make the immune system attack the cancer cells. One of the most popular vaccines for non-small cell lung cancer treatment is called Cimavax, which is developed in Cuba. So, let us find out how Cimavax fares and functions in comparison with the other lung cancer treatment options.
Epidermal Growth Factor (EGF) is a protein present in our body. A patient suffering from lung cancer produces too much EGF that allows the cells uncontrollably grow and spread. Cimavax has been developed to let the body produce antibodies for recognizing and binding EGF. The vaccine makes EGF stop attaching to the cancer cell receptors, which curbs the growth and spread of the cells.
Several research and studies show that Cimavax has improved survival among many lung cancer patients in Cuba. On top of that, the vaccine is also claimed to be safe and less painful than other lung cancer treatment options.
Popularly known as Radiotherapy, this treatment can to reduce and control lung cancer symptoms. However, the biggest drawback of this option is its side effects. During the treatment, high dose of radiation is transmitted to the cancer tissues and the surrounding tissues. This often makes way for various side effects like lung scarring, shortness of breath, stiff shoulder, itchy peeling skin, general weakness and more. However, researchers are searching for the reduction of the side effects and predicting who will respond to radiotherapy before they start the treatment.
This is one of the most common treatments for both small cell and non-small cell lung cancer. The treatment plan often includes various drug combinations. Research is still being pursued to improve the doses of drugs and the timing of use. For people with Stage III lung cancer, doctors often recommend the combination of chemotherapy and high dose radiotherapy. For Stage IV patients, chemotherapy is usually the main treatment where radiation is used for symptoms palliation only.
This is applicable mostly for the Stage I and Stage II non-small cell lung cancer patients to remove the tumor. A surgeon removes the section that contains the tumor or the lobe, for this procedure. Video Assisted Thoracoscopic Surgery, popularly known as VATS is used by some surgeons for the procedure. A tube called thoracoscope is inserted in the chest after making a small incision. The surgeon can see inside the chest, as thoracoscope is fitted with a small camera and light. He/she can then remove the lung lobe through the scope without a large chest incision.
Targeted treatment is definitely one of the most exciting lung cancer medicine advancements. When the drugs used in chemotherapy cannot differentiate between the cancer cells and the normal cells, targeted treatments specifically attack the cancer cells only. The doctors may advice advanced lung cancer patients with certain molecular biomarker with such targeted drugs. Sometimes, it can be combined with chemotherapy as well.
In comparison to all the options for lung cancer mentioned-above, Cimavax is much safer. Due to the low toxicity of the vaccine, the side effects are mild, which includes feeling sick, fever and chills. In several trials that took place in Cuba, it showed a trend of improved survival. Moreover, Cimavax is easy to produce and store, which also makes it affordable.
If you want to learn more about how Cimavax can help lung cancer patients, please contact PlacidWay. Click the button below: